@FierceMedDev: Cardiac Science sells off diagnostic biz, focuses on defibrillators. News | Follow @FierceMedDev
@MarkHFierce: Folks have figured out a way to goose Dx tech that could enable personalized prostate cancer treatments. Release | Follow @MarkHFierce
@DamianFierce: Now, per Reuters, Thermo Fisher is in the lead with a $12B bid on Life Tech. More | Follow @DamianFierce
> Acclarent, a division of Johnson & Johnson ($JNJ), got served with an FDA warning letter for changing a device's training materials without notifying the agency. Letter
> GnuBIO has launched beta versions of its desktop DNA sequencing system, which the company says is cheaper and faster than its competitors. Article
> Maine's NorDx is expanding its diagnostic capabilities with hematology analysis technology acquired from Japan's Sysmex. Release
> According to a new study, excercise doesn't raise the risk of errant shocks in heart failure patients implanted with ICDs. Story
> Sandia National Laboratories developed a diagnostic device--a lab on a disk--designed to screen for anthrax, ricin or other bioterror agents. Story
> T2 Biosystems has secured another patent to cover T2Candida, its blood diagnostic for the sepsis-causing infection. Item
> California startup Adagio Medical raised $2.5 million toward developing novel devices to treat cardiovascular disease. Story
Biotech News
@FierceBiotech: Elan closes $3.25B Tysabri deal and preps for biotech deal spree. News | Follow @FierceBiotech
@JohnCFierce: AstraZeneca's latest biotech deal offers more early-stage research work. Years away from PhIII, where it needs help. More | Follow @JohnCFierce.
@RyanMFierce: Pfizer made an another early-stage deal with a Cambridge, MA biotech. This one with Gates-backed Tetragenics. Release | Follow @RyanMFierce
> AstraZeneca gambles on cardio therapy in AlphaCore buyout. Report
> Resurgent Pfizer partners with Bind on new nanotech drug effort. News
> Biotech gamblers crowd high-stakes game for Sarepta. More
Pharma News
@FiercePharma: Tough German pricing authority backs Pfizer/BMS drug Eliquis as stroke preventive; 'significant' benefit. Report | Follow @FiercePharma
@EricPFierce: Lilly is installing some new technology in its US insulin cartridge plant, to pump up output. Article | Follow @EricPFierce
> Pfizer, Novartis eye bids for Brazil's Ache in deal worth $5B. Story
> South Africa's Adcock Ingram rebuffs buyout by conglomerate. More
> Valeant fires back at Merz with $415M-plus Obagi bid. News
Biomarkers News
@EmilyMFierce: New prostate cancer predictors revealed. Report | Follow @EmilyMFierce
> CV biomarker study finds evidence of bias, exaggeration in the field. Story
> French researchers cast doubt on chemo biomarker's viability. Item
> Biomarkers predict risk of diabetes-related kidney trouble. Article
> U.K. team concocts rapid approach for colorectal cancer biomarker detection. More
Drug Delivery News
@MichaelGFierce: Biogen Idec's new oral MS drug Tecfidera has an unknown mechanism of action, the company says. More | Follow @MichaelGFierce
> Cholesterol 'rafts' enable cancer-killing delivery of DNA, RNA. Report
> Analysts expect nanotech drug delivery boom despite safety concerns. Story
> Pozen seeks FDA approval for layered aspirin cardiovascular treatment. Item
> FDA rejects A.P. Pharma's delayed-onset chemo drug. More
> Entrega, other startups make strides in needle-free delivery. Article